Premium
Risk of placenta‐mediated pregnancy complications or pregnancy‐related VTE in VTE ‐asymptomatic families of probands with VTE and heterozygosity for factor V L eiden or G 20210 prothrombin mutation
Author(s) -
Cordoba Iris,
Pegenaute Carlota,
GonzálezLópez Tomás José,
Chillon Carmen,
Sarasquete Maria Eugenia,
MartinHerrero Francisco,
Guerrero Carmen,
Cabrero Mónica,
Garcia Sanchez Maria Helena,
Pabon Pedro,
Lozano Francisco Santiago,
Gonzalez Marcos,
Alberca Ignacio,
GonzálezPorras José Ramón
Publication year - 2012
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2012.01809.x
Subject(s) - medicine , pregnancy , factor v leiden , asymptomatic , odds ratio , obstetrics , risk factor , thrombophilia , placental abruption , population , preeclampsia , gynecology , thrombosis , venous thrombosis , fetus , genetics , environmental health , biology
Background Few studies have evaluated the risk of pregnancy‐related adverse events in asymptomatic relatives of probands for VTE and factor V Leiden or the G 20210 A variant. The antepartum management of this population ranges from antepartum anticoagulation therapy to clinical surveillance. Objective To evaluate the risk of placenta‐mediated pregnancy complications and pregnancy‐related VTE in VTE ‐asymptomatic families of probands with VTE and who are heterozygous carriers of either factor V Leiden or PT ‐ G 20210 A mutation. Methods One hundred and fifty‐eight relatives, who had 415 pregnancies, were retrospectively evaluated. Odds ratios and 95% confidence intervals were calculated to compare pregnancy outcomes between women with and without thrombophilia. Results In the factor V Leiden group, 22 placenta‐mediated pregnancy events of 152 pregnancies (14.4%) were reported, compared with 25 adverse events of 172 pregnancies in the G20210A prothrombin group (14.5%) and 13 adverse events of 91 pregnancies in the non‐carrier group (14.2%). Carriers of factor V L eiden or G 20210 A prothrombin were not associated with a higher risk of pregnancy‐adverse outcomes compared with non‐carriers: OR 1.02 (95% CI , 0.40–2.25) and 1.25 (95% CI , 0.48–3.24), respectively. Four episodes of pregnancy‐associated VTE of 415 pregnancies (0.96%) were recorded. Two episodes of VTE in the G 20210 A group, one in the factor V Leiden group, and one episode in the non‐carrier group were noted. Conclusions In VTE ‐asymptomatic relatives of probands with VTE , the presence of factor V L eiden or the G 20210 A prothrombin mutation in heterozygosis should not lead to a decision to instigate antepartum prophylaxis.